ScoreWhy is Strides Pharma Science Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.83%
- Poor long term growth as Net Sales has grown by an annual rate of 7.94% and Operating profit at 11.02% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.90 times
2
With a growth in Net Profit of 54.96%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 11 consecutive quarters
- OPERATING PROFIT TO INTEREST(Q) Highest at 5.77 times
- ROCE(HY) Highest at 17.96%
- DEBT-EQUITY RATIO(HY) Lowest at 0.57 times
3
With ROCE of 15.5, it has a Attractive valuation with a 2.6 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 64.10%, its profits have fallen by -14.9%
4
27.27% of Promoter Shares are Pledged
- In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Strides Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Strides Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Strides Pharma
64.1%
1.61
39.76%
Sensex
-7.23%
-0.56
13.01%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.94%
EBIT Growth (5y)
11.02%
EBIT to Interest (avg)
1.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.50
Sales to Capital Employed (avg)
0.81
Tax Ratio
14.08%
Dividend Payout Ratio
1.03%
Pledged Shares
27.27%
Institutional Holding
43.14%
ROCE (avg)
7.49%
ROE (avg)
9.60%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
35
Price to Book Value
3.40
EV to EBIT
16.74
EV to EBITDA
13.08
EV to Capital Employed
2.60
EV to Sales
2.49
PEG Ratio
NA
Dividend Yield
0.35%
ROCE (Latest)
15.54%
ROE (Latest)
18.64%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
OPERATING PROFIT TO INTEREST(Q)
Highest at 5.77 times
ROCE(HY)
Highest at 17.96%
DEBT-EQUITY RATIO(HY)
Lowest at 0.57 times
PBDIT(Q)
Highest at Rs 239.71 cr.
PBT LESS OI(Q)
Highest at Rs 146.33 cr.
NET SALES(Q)
Highest at Rs 1,323.47 cr
PAT(Q)
At Rs 132.54 cr has Grown at 27.1%
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Strides Pharma
Operating Profit to Interest - Quarterly
Highest at 5.77 times and Grown
each quarter in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Operating Profit (PBDIT) - Quarterly
Highest at Rs 239.71 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 146.33 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.57 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales - Quarterly
Highest at Rs 1,323.47 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 146.33 cr has Grown at 20.12%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 132.54 cr has Grown at 27.1%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
